SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood

作者：Dianna L. Ng, Gregory Mark Goldgof, Brian Rudolph Shy, Andrew G. Levine, Joanna Balcerek, Sagar P. Bapat, John C. Prostko, Mary A. Rodgers, Kelly Elizabeth Coller, Sandra Pearce, Sergej Franz, Li Du, Mars Stone, Satish K. Pillai, Alicia Sotomayor-González, Venice Servellita, Claudia Sánchez-San Martín, Andrea C. Granados, Dustin R. Glasner, Lucy M. Han, Kent Truong, Naomi Akagi, David N. Nguyen, Neil M. Neumann, Daniel Qazi, Elaine D. Hsu, Wei Jie Gu, Yale A. Santos, Brian Custer, Valerie Green, Phillip C. Williamson, Nancy K. Hills, Chuanyi Mark Lu, Jeffrey D. Whitman, Susan L. Stramer, Candace Wang, Kevin R. Reyes, Jill M. C. Hakim, Kirk Sujishi, Fariba Alazzeh, Lori Pham, Edward C. Thornborrow, Ching-Ying Oon, Steve A. Miller, Theodore W. Kurtz, Graham Simmons, John Hackett, Michael Paul Busch, Charles Y. Chiu · 发表于：Nature Communications · 年份：2020 · DOI：10.1038/s41467-020-18468-8 · 被引用次数：183 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、SARS-CoV-2 detection and testing

Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3-11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.